Those taking amycretin lost almost a quarter of their body weight in 36 weeks, the best result yet for a GLP drug
Those taking amycretin lost almost a quarter of their body weight in 36 weeks, the best result yet for a GLP drug
Copy link
Eli Lilly’s orforglipron could offer needle-free alternative to weight-loss jabs at lower cost
Participants in trial of amycretin injectable obesity drug lost an average of 24% of their body weight on highest dose
The tablet - orforglipron - is available in the US and could soon launch in the UK.
The pill doesn’t have the fasting requirements of many other weight loss drugs
GLP-1 users likely to regain two-thirds of the weight they lost within a year, study shows
A new pill developed by the British pharma firm AstraZeneca appears to help people lose a similar amount of weight to other GLP-1…
